Subscribe To
89bio publishes positive results from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) in nature medicine
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorab...
June 24, 2023, 9:05 am
Amarin partner eddingpharm receives regulatory approval for vascepa® (icosapent ethyl) in mainland china
— VASCEPA Approved by the National Medical Products Administration (NMPA) as an Adjunct to Diet to Reduce Triglyceride Levels in Adult Patients with...
June 1, 2023, 10:00 am
Why shares of 89bio soared this week
89bio's lead therapy pegozafermin is seen as a treatment for NASH and hypertriglyceridemia. No NASH dru...
March 24, 2023, 10:57 am
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG ...
March 4, 2023, 6:30 pm
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
February 21, 2023, 8:00 am
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
February 21, 2023, 8:00 am
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
February 21, 2023, 8:00 am
Medicinova receives a notice of allowance for a new patent covering mn-001 and mn-002 for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia in brazil
LA JOLLA, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) an...
January 10, 2023, 3:00 am
This analyst thinks 89bio's pegozafermin data has exceeded expectations
In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe ...
July 11, 2022, 2:24 pm
89bio posts promising pegozafermin data for severe hypertriglyceridemia
89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe ...
June 29, 2022, 6:07 am
Ionis, pfizer scrap plans for experimental cardiovascular drug
Shares of Ionis Pharmaceuticals Inc. IONS, +5.11% fell 7.9% in premarket trading on Monday after the company and Pfizer Inc. PFE, +1.80% said they dis...
January 31, 2022, 7:41 am
Ionis, pfizer scrap plans for experimental cardiovascular drug
Shares of Ionis Pharmaceuticals Inc. IONS, +5.11% fell 7.9% in premarket trading on Monday after the company and Pfizer Inc. PFE, +1.80% said they dis...
January 31, 2022, 7:41 am
Ionis, pfizer scrap plans for experimental cardiovascular drug
Shares of Ionis Pharmaceuticals Inc. IONS, +5.11% fell 7.9% in premarket trading on Monday after the company and Pfizer Inc. PFE, +1.80% said they dis...
January 31, 2022, 7:41 am
Liminal biosciences pauses development of fezagepras, outlines r&d priorities for 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it woul...
January 20, 2022, 6:52 am
Liminal biosciences pauses development of fezagepras, outlines r&d priorities for 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it woul...
January 20, 2022, 6:52 am
Liminal biosciences pauses development of fezagepras, outlines r&d priorities for 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it woul...
January 20, 2022, 6:52 am